Proteasome inhibitors in the treatment of multiple myeloma

Expert Review of Anticancer Therapy

Volumn 13, Issue 3, 2013, Pages 339-358

  Mcbride, Ali ^a   Ryan, Patricia Y ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

bortezomib; carfilzomib; marizomib; MLN9708; multiple myeloma; peripheral neuropathy; proteasome inhibitors

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DELANZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; IXAZOMIB; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; OPROZOMIB; PANOBINOSTAT; PLACEBO; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; RECOMBINANT ALPHA2B INTERFERON; SALINOSPORAMIDE A; THALIDOMIDE; VINCRISTINE; VORINOSTAT;

ACUTE KIDNEY FAILURE; ANEMIA; ANOREXIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME ABERRATION; CONGESTIVE HEART FAILURE; CONSTIPATION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; DYSPNEA; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; EPIGLOTTITIS; FATIGUE; FEASIBILITY STUDY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEALTH ECONOMICS; HEART ARREST; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; HYPOPHOSPHATEMIA; INSOMNIA; KIDNEY DYSFUNCTION; LEUKOPENIA; LOW DRUG DOSE; LUNG DISEASE; LYMPHOCYTOPENIA; METHEMOGLOBINEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NEURALGIA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; STEM CELL MOBILIZATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS REACTIVATION; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MULTIPLE MYELOMA; PROTEASOME INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84874852282     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.9     Document Type: Review

References (118)

1. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5), 2516-2520 (2008).
2. Anderson KC, Alsina M, Bensinger W et al.; National Comprehensive Cancer Network. Multiple myeloma. J. Natl Compr. Canc. Netw. 9(10), 1146-1183 (2011).
3. Ludwig H, Avet-Loiseau H, Bladé J et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist 17(5), 592-606 (2012).
4. Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4(5), 349-360 (2004).
5. Moreau P, Pylypenko H, Grosicki S et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, Phase 3, non-inferiority study. Lancet Oncol. 12(5), 431-440 (2011).
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012).
7. Siegel R, DeSantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62(4), 220-241 (2012).
8. Kyle RA, Buadi F, Rajkumar SV. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology 25(7), 578-586 (2011).
9. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 121, 749-757 (2003).
10. Durie BG, Harousseau JL, Miguel JS et al.; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 20(9), 1467-1473 (2006).
11. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78(1), 21-33 (2003).
12. Dimopoulos MA, Terpos E, Chanan-Khan A et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J. Clin. Oncol. 28(33), 4976-4984 (2010).
13. Avet-Loiseau H, Magrangeas F, Moreau P et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J. Clin. Oncol. 29, 1893-1897 (2011).
14. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol. 23(26), 6333-6338 (2005).
15. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 7(8), 585-598 (2007).
16. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J. Clin. Oncol. 23(15), 3412-3420 (2005).
17. Grzasko N, Hus M, Pluta A et al. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol. Oncol. doi:10.1002/hon.2018 (2012) (Epub ahead of print).
18. Nemec P, Zemanova Z, Kuglik P et al.; Czech Myeloma Group. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk. Lymphoma 53(5), 920-927 (2012).
19. Avet-Loiseau H, Attal M, Campion L et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J. Clin. Oncol. 30(16), 1949-1952 (2012).
20. Johnson SK, Heuck CJ, Albino AP et al. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int. J. Hematol. 94(4), 321-333 (2011).
21. Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J. Clin. Oncol. 30(4), 445-452 (2012).
22. Cavo M, Rajkumar SV, Palumbo A et al.; International Myeloma Working Group. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117(23), 6063-6073 (2011).
23. Barlogie B, Attal M, Crowley J et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J. Clin. Oncol. 28(7), 1209-1214 (2010).
24. Cavo M, Tosi P, Zamagni E et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J. Clin. Oncol. 25(17), 2434-2441 (2007).
25. Ludwig H, Durie BG, McCarthy P et al.; International Myeloma Working Group. IMWG consensus on maintenance therapy in multiple myeloma. Blood 119(13), 3003-3015 (2012).
26. Dimopoulos MA, Lacy MQ, Moreau P et al. Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/ refractory MM: a Phase 3, multicenter, randomized, open-label study. Blood 120, LBA6, Abstract LBA6 (2012).
27. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat. Rev. 29(Suppl. 1), 3-9 (2003).
28. Meister S, Schubert U, Neubert K et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67(4), 1783-1792 (2007).
29. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107(12), 4907-4916 (2006).
30. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 5(1), 18 (2005).
31. Demchenko YN, Kuehl WM. A critical role for the NFkB pathway in multiple myeloma. Oncotarget 1(1), 59-68 (2010).
32. Kupperman E, Lee EC, Cao Y et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70(5), 1970-1980 (2010).
33. San Miguel JF, Schlag R, Khuageva NK et al.; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359(9), 906-917 (2008).
34. Bringhen S, Larocca A, Rossi D et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116(23), 4745-4753 (2010).
35. Palumbo A, Bringhen S, Rossi D et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol. 28(34), 5101-5109 (2010).
36. Mateos MV, Oriol A, Martínez-López J et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 11(10), 934-941 (2010).
37. Demo SD, Kirk CJ, Aujay MA et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67(13), 6383-6391 (2007).
38. Papadopoulos KP, Lee P, Singhal S et al. A Phase 1b/2 study of prolonged infusion carflizomib in patients with relapsed and/ or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007. Blood 118, Abstract 2930 (2011).
39. Chauhan D, Catley L, Li G et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8(5), 407-419 (2005).
40. Piva R, Ruggeri B, Williams M et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111(5), 2765-2775 (2008).
41. Hurchla MA, Garcia-Gomez A, Hornick MC et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia doi:10.1038/leu.2012.183 (2012) (Epub ahead of print).
42. Richardson PG, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609-2617 (2003).
43. Richardson PG, Barlogie B, Berenson J et al. Extended follow-up of a Phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer 106(6), 1316-1319 (2006).
44. Jagannath S, Barlogie B, Berenson J et al. A Phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 127(2), 165-172 (2004).
45. Jagannath S, Barlogie B, Berenson JR et al. Updated survival analyses after prolonged follow-up of the Phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br. J. Haematol. 143(4), 537-540 (2008).
46. Richardson PG, Sonneveld P, Schuster MW et al.; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24), 2487-2498 (2005).
47. Richardson PG, Sonneveld P, Schuster M et al. Extended follow-up of a Phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110(10), 3557-3560 (2007).
48. Orlowski RZ, Nagler A, Sonneveld P et al. Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 25(25), 3892-3901 (2007).
49. Arnulf B, Pylypenko H, Grosicki S et al. Updated survival analysis of a randomized Phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 97(12), 1925-1928 (2012).
50. Garderet L, Iacobelli S, Moreau P et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomidedexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/ IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 30(20), 2475-2482 (2012).
51. Dimopoulos MA, Jagannath S, Yoon S et al. VANTAGE088: final results from the global Phase 3 trial of the multi-histone deacetylase inhibitor vorinostat in combination with bortezomib in relapsed/ refractory multiple myeloma. Haematologica 97, Abstract 0281 (2012).
52. Petrucci MT, Giraldo P, Corradini P et al. A prospective, international Phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br. J. Haematol. doi:10.1111/bjh.12198 (2013) (Epub ahead of print).
53. Reddy N, Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Ann. Oncol. 21(9), 1756-1764 (2010).
54. Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. Semin. Hematol. 49(3), 228-242 (2012).
55. Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin. Hematol. 49(Suppl. 1), S16-S32 (2012).
56. Richardson PG, Weller E, Jagannath S et al. Multicenter, Phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J. Clin. Oncol. 27(34), 5713-5719 (2009).
57. Alsina M, Trudel S, Furman RR et al. A Phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin. Cancer Res. 18(17), 4830-4840 (2012).
58. San Miguel JF, Schlag R, Khuageva NK et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan- prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J. Clin. Oncol. 31(4), 448-455 (2013).
59. Harousseau JL, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 Phase III trial. J. Clin. Oncol. 28(30), 4621-4629 (2010).
60. Sonneveld P, Schmidt-Wolf IG, van der Holt B et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized Phase III HOVON-65/ GMMG-HD4 trial. J. Clin. Oncol. 30(24), 2946-2955 (2012).
61. Cavo M, Tacchetti P, Patriarca F et al.; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised Phase 3 study. Lancet 376(9758), 2075-2085 (2010).
62. Rosiñol L, Oriol A, Teruel AI et al.; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized Phase 3 PETHEMA/GEM study. Blood 120(8), 1589-1596 (2012).
63. van de Velde HJ, Liu X, Chen G et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92, 1399-1406 (2007).
64. Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology Am. Soc. Hematol. Educ. Program 2012, 354-361 (2012).
65. Moreau P, Avet-Loiseau H, Facon T et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118(22), 5752-5758; quiz 5982 (2011).
66. Kumar S, Flinn I, Richardson PG et al. Randomized, multicenter, Phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119(19), 4375-4382 (2012).
67. Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5), 679-686 (2010).
68. Kropff M, Liebisch P, Knop S et al.; Deutsche Studiengruppe Multiples Myelom, DSMM. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/ dexamethasone for remission induction in patients with newly diagnosed myeloma. Ann. Hematol. 88(11), 1125-1130 (2009).
69. Reeder CB, Reece DE, Kukreti V et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 115(16), 3416-3417 (2010).
70. Cavo M, Pantani L, Petrucci MT et al.; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Bortezomib-thalidomide- dexamethasone is superior to thalidomidedexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120(1), 9-19 (2012).
71. Ladetto M, Ferrero S, Drandi D et al. Long-term results of the GIMEMA VTD consolidation trial in autografted multiple myeloma patients (VEL-03-096): impact of minimal residual disease detection by real time quantitative PCR on late recurrences and overall survival. Blood 118, 376-377, Abstract 827 (2011).
72. Mellqvist UH, Gimsing P, Hjertner O et al. Improved progression-free survival with bortezomib consolidation after high dose melphalan: results of a randomized Phase III trial. Haematologica 96, S31, Abstract O-11 (2011).
73. Siegel DS, Martin T, Wang M et al. A Phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14), 2817-2825 (2012).
74. Kumar SK, Lee JH, Lahuerta JJ et al.; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1), 149-157 (2012).
75. Jagannath S, Vij R, Stewart AK et al. An open-label single-arm pilot Phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin. Lymphoma. Myeloma Leuk. 12(5), 310-318 (2012).
76. Vij R, Wang M, Kaufman JL et al. An open-label, single-arm, Phase 2 (PX-171- 004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119(24), 5661-5670 (2012).
77. Vij R, Siegel DS, Jagannath S et al. An open-label, single-arm, Phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br. J. Haematol. 158(6), 739-748 (2012).
78. Niesvizky R, Wang L, Orlowski RZ et al. Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM). Blood 114, 128-129, Abstract 304 (2009).
79. Moreau P, Hulin C, Caillot D et al. Phase I/II study of carfilzomib plus melphalanprednisone (CMP) in elderly patients with de novo multiple myeloma. Haematologica 97, 116, Abstract 0287 (2012).
80. Jakubowiak AJ, Dytfeld D, Griffith KA et al. A Phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120(9), 1801-1809 (2012).
81. Sonneveld P, Hacker E, Zweegman S et al. Carflizomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM). A trial of the European Myeloma Network (EMN). Blood 118, Abstract 633 (2011).
82. Mikhael J, Reeder CB, Libby EN et al. A Phase I/II trial of cyclophosphamide, carfilzomib, thalidomide, and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. J. Clin. Oncol. 30, Abstract 8010 (2012).
83. Lonial S, Baz RC, Wang M et al. Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM). J. Clin. Oncol. 30, 8017, Abstract 8017 (2012).
84. Kumar S, Bensinger W, Reeder CB et al. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): a Phase I study. J. Clin. Oncol. 30, 8034, Abstract 8034 (2012).
85. Richardson P, Berdeja JG, Niesvizky R et al. MLN9708, an investigational proteasome inhibitor, combined with lenalidomide and dexamethasone in previously untreated multiple myeloma patients: evaluation of weekly and twice-weekly dosing regimens. Haematologica 97, 473-474, Abstract 1144 (2012).
86. San Miguel J, Hajek R, Spicka I et al. Oral MLN9708, an investigational proteasome inhibitor, in combination with melphalan and prednisone in patients with previously untreated multiple myeloma: a Phase 1 study. Haematologica 97, 118-119, Abstract 0293 (2012).
87. Richardson PG, Spencer A, Cannell P et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/ refractory multiple myeloma (MM). Blood 118, 140-141, Abstract 302 (2011).
88. Sawyer Jr. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 204(1), 3-12 (2011).
89. Avet-Loiseau H, Leleu X, Roussel M et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28(30), 4630-4634 (2010).
90. Cavo M, Bringhen S, Terragna C et al. Bortezomib-based induction treatments improve outcomes of newly diagnosed multiple myeloma patients with high-risk cytogenetic abnormalities. Blood 116, 342a-343a, Abstract 781 (2010).
91. Goldschmidt H, Neben K, Bertsch U et al. Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with gain 1q21 and t(4;14) - a subgroup analysis of the HOVON-65/ GMMG-HD4 trial. Blood 116, 138a-139a, Abstract 305 (2010).
92. Mateos MV, Gutiérrez NC, Martín-Ramos ML et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood 118(17), 4547-4553 (2011).
93. Reece D, Rodriguez GP, Szwajcer D et al. Phase II trial of bortezomib-based therapy without ASCT in newly diagnosed patients with t(4;14) multiple myeloma. Haematologica 96(Suppl. 1), S95, Abstract P-220 (2011).
94. Neben K, Lokhorst HM, Jauch A et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119(4), 940-948 (2012).
95. Jakubowiak A, Siegel DS, Singhal S et al. Unfavorable cytogenetic characterisitics do not adversely impact response rates in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib on the 003 (A1) study. Blood 118, Abstract 1875 (2011).
96. Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin. Cancer Res. 18(8), 2145-2163 (2012).
97. Harvey RD, Lonial S, Patel P et al. Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction, including patients on hemodialysis. Haematologica 97, 346, Abstract 0844 (2012).
98. Zangari M, Terpos E, Zhan F, Tricot G. Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat. Rev. 38(8), 968-980 (2012).
99. Zangari M, Aujay M, Zhan F et al. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur. J. Haematol. 86(6), 484-487 (2011).
100. Richardson PG, Delforge M, Beksac M et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26(4), 595-608 (2012).
101. Dimopoulos MA, Mateos MV, Richardson PG et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan- prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the Phase 3 VISTA study. Eur. J. Haematol. 86(1), 23-31 (2011).
102. Richardson PG, Sonneveld P, Schuster MW et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the Phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br. J. Haematol. 144(6), 895-903 (2009).
103. Singhal S, Siegel DS, Martin T et al. Integrate safety from Phase 2 studies of monotherapy carflizomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. Blood 118, Abstract 1876 (2011).
104. Nooka AJ, Badros AZ, Patel P et al. Hematologic safety data from four Phase II studies of single agent carfilzomib in relapsed and/or refractory multiple myeloma. J. Clin. Oncol. 30, Abstract 8086 (2012).
105. Lonial S, Richardson PG, San Miguel J et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br. J. Haematol. 143(2), 222-229 (2008).
106. Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/ lenalidomide-based therapy: review of data from Phase 3 trials and studies of novel combination regimens. Clin. Lymphoma. Myeloma Leuk. 11(2), 228-236 (2011).
107. Zhou HJ, Aujay MA, Bennett MK et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J. Med. Chem. 52(9), 3028-3038 (2009).
108. Chauhan D, Singh AV, Aujay M et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116(23), 4906-4915 (2010).
109. Sanchez E, Li M, Steinberg JA et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br. J. Haematol. 148(4), 569-581 (2010).
110. Gallerani E, Zucchetti M, Brunelli D et al. A first in human Phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur. J. Cancer 49(2), 290-296 (2013).
111. Kuhn DJ, Orlowski RZ. The immunoproteasome as a target in hematologic malignancies. Semin. Hematol. 49(3), 258-262 (2012).
112. Singh AV, Bandi M, Aujay MA et al. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br. J. Haematol. 152(2), 155-163 (2011).
113. Mateos MV, Oriol A, Martínez-López J et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120(13), 2581-2588 (2012).
114. Niesvizky R, Flinn IW, Rifkin R et al. efficacy and safety of three bortezomibbased combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, Phase 3b UPFRONT study. Blood 118, Abstract 478, Abstract # (2011).
115. Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 15(5-6), 243-249 (2010).
116. ClinicalTrials.gov. www.clinicaltrials.gov.
117. Onyx Pharmaceuticals, Inc. KYPROLIS™ (carfilzomib) for injection, for intravenous use. Prescribing information, revised July 2012. www.accessdata.fda.gov/drugsatfda-docs/ label/2012/202714lbl.pdf
118. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Multiple Myeloma; Version 1.2013 www.nccn.org/professionals/physician-gls/ pdf/myeloma.pdf